193 related articles for article (PubMed ID: 26183396)
1. Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling.
Zhao Y; Yang X
Oncotarget; 2015 Sep; 6(26):21906-17. PubMed ID: 26183396
[TBL] [Abstract][Full Text] [Related]
2. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway.
Zhao Y; Khanal P; Savage P; She YM; Cyr TD; Yang X
Cancer Res; 2014 Aug; 74(16):4493-503. PubMed ID: 24812269
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy.
Wang Z; Chen X; Zhong MZ; Yang S; Zhou J; Klinkebiel DL; Karpf AR; Chen Y; Dong J
Cell Signal; 2018 Dec; 52():137-146. PubMed ID: 30223016
[TBL] [Abstract][Full Text] [Related]
4. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.
Lai D; Ho KC; Hao Y; Yang X
Cancer Res; 2011 Apr; 71(7):2728-38. PubMed ID: 21349946
[TBL] [Abstract][Full Text] [Related]
5. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
Chang WL; Yu CC; Chen CS; Guh JH
Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
[TBL] [Abstract][Full Text] [Related]
6. CDK1 phosphorylation of TAZ in mitosis inhibits its oncogenic activity.
Zhang L; Chen X; Stauffer S; Yang S; Chen Y; Dong J
Oncotarget; 2015 Oct; 6(31):31399-412. PubMed ID: 26375055
[TBL] [Abstract][Full Text] [Related]
7. Identification of Cdk1-LATS-Pin1 as a Novel Signaling Axis in Anti-tubulin Drug Response of Cancer Cells.
Yeung B; Khanal P; Mehta V; Trinkle-Mulcahy L; Yang X
Mol Cancer Res; 2018 Jun; 16(6):1035-1045. PubMed ID: 29523761
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
9. Validation of chemical compound library screening for transcriptional co-activator with PDZ-binding motif inhibitors using GFP-fused transcriptional co-activator with PDZ-binding motif.
Nagashima S; Maruyama J; Kawano S; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Nishina H; Hata Y
Cancer Sci; 2016 Jun; 107(6):791-802. PubMed ID: 27009852
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.
Cao X; Zhao B
Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132
[TBL] [Abstract][Full Text] [Related]
11. Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
Khanal P; Yeung B; Zhao Y; Yang X
Sci Rep; 2019 Apr; 9(1):6394. PubMed ID: 31015482
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.
Wertz IE; Kusam S; Lam C; Okamoto T; Sandoval W; Anderson DJ; Helgason E; Ernst JA; Eby M; Liu J; Belmont LD; Kaminker JS; O'Rourke KM; Pujara K; Kohli PB; Johnson AR; Chiu ML; Lill JR; Jackson PK; Fairbrother WJ; Seshagiri S; Ludlam MJ; Leong KG; Dueber EC; Maecker H; Huang DC; Dixit VM
Nature; 2011 Mar; 471(7336):110-4. PubMed ID: 21368834
[TBL] [Abstract][Full Text] [Related]
13. The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFβ-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition.
Huang W; Lv X; Liu C; Zha Z; Zhang H; Jiang Y; Xiong Y; Lei QY; Guan KL
J Biol Chem; 2012 Jul; 287(31):26245-53. PubMed ID: 22692215
[TBL] [Abstract][Full Text] [Related]
14. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
15. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
[TBL] [Abstract][Full Text] [Related]
16. Phase separation of TAZ compartmentalizes the transcription machinery to promote gene expression.
Lu Y; Wu T; Gutman O; Lu H; Zhou Q; Henis YI; Luo K
Nat Cell Biol; 2020 Apr; 22(4):453-464. PubMed ID: 32203417
[TBL] [Abstract][Full Text] [Related]
17. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
Kedan A; Verma N; Saroha A; Shreberk-Shaked M; Müller AK; Nair NU; Lev S
Cell Death Dis; 2018 Sep; 9(10):985. PubMed ID: 30250159
[TBL] [Abstract][Full Text] [Related]
18. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
19. The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway.
Zhu Y; He D; Bo H; Liu Z; Xiao M; Xiang L; Zhou J; Liu Y; Liu X; Gong L; Ma Y; Zhou Y; Zhou M; Xiong W; Yang F; Xing X; Li R; Li W; Cao K
Oncogene; 2019 Aug; 38(32):6065-6081. PubMed ID: 31273338
[TBL] [Abstract][Full Text] [Related]
20. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
